Resolution Therapeutics focused investor attention this week on its EMERALD Phase I/II trial of RTX001, a first-in-class regenerative macrophage therapy for end-stage liver disease. The company tied its outreach to World Liver Day, highlighting the global burden of liver disease and the lack of options beyond transplantation.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The EMERALD trial is running across 15 sites in the U.K. and Spain, with the interim analysis cohort now fully recruited and a data readout targeted for the end of Q3 2026. Management signaled that interim data expected later this year could be a key catalyst, providing early safety and efficacy signals for RTX001.
Resolution used the Advanced Therapies Congress in London to showcase RTX001 and its broader regenerative macrophage platform for inflammatory and fibrotic diseases. Conference talks and posters reportedly drew strong interest, while the EMERALD program won “Best Therapeutic R&D Programme of the Year” at the 2026 One Nucleus Awards.
To bolster execution, the company appointed Louise Rowe as Vice President of Operations, adding more than 30 years of cell and gene therapy development and commercialization experience. Her background includes leading Libmeldy to European approval at Orchard Therapeutics and advancing AVB 101 at AviadoBio through IND clearance and FDA Fast Track designation.
Resolution also emphasized early work on scalable, AI- and automation-enabled manufacturing and supply chain capabilities to support commercially sustainable cell and gene therapies. In parallel, VP of IP & Technology Strategy Eli Gilsohn was named to World Intellectual Property Review’s Global In-House Elite 2026 list, underscoring the company’s focus on strengthening its IP portfolio.
The company’s public health messaging around lifestyle modification and liver disease prevention, aligned with organizations such as the British Liver Trust, enhances its visibility in a high-need therapeutic area. Overall, Resolution Therapeutics enters the coming quarters with growing clinical momentum, operational depth, and external recognition as it approaches the crucial EMERALD interim data readout.